Drug Manufacturers - General · Miami, Florida, United States
$0.90
-3.46% (-$0.03)2026-07-09
Smart-Money SignalNeutral · 52/100— Insider open-market flow is flat over 90 days
Net Income-$2.4M
EPS$-0.11
Market Cap$15.2M
Price Performance
Historical data including institutional events
Company Profile
E
Erez Aminov
CEO & Executive Director
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
